(Q37741793)

22 August 2017

1 reference

title

Treatment of localized prostate cancer: when is active surveillance appropriate? (English)

1 reference

22 August 2017

1 reference

Peter C Albertsen

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

4 May 2010

1 reference

Nature Reviews Clinical Oncology

22 August 2017

published in

1 reference

22 August 2017

volume

7

1 reference

22 August 2017

issue

7

1 reference

22 August 2017

page(s)

394-400

1 reference

22 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Active surveillance for early-stage prostate cancer: review of the current literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Screening and prostate-cancer mortality in a randomized European study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Mortality results from a randomized prostate-cancer screening trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

The influence of finasteride on the development of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

An updated catalog of prostate cancer predictive tools

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Validation of the partin nomogram for prostate cancer in a national sample.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Critical review of prostate cancer predictive tools

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

20-year outcomes following conservative management of clinically localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Outcomes of localized prostate cancer following conservative management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Prostate cancer and the Will Rogers phenomenon.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Natural History of Early, Localized Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Active surveillance for the management of prostate cancer in a contemporary cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Quality of life and satisfaction with outcome among prostate-cancer survivors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Duration of androgen suppression in the treatment of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

National practice patterns and time trends in androgen ablation for localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Survival following primary androgen deprivation therapy among men with localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.63

Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer

31 March 2020

1 reference

12 December 2020

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

12 December 2020

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

12 December 2020

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1 reference

12 December 2020

Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study

1 reference

12 December 2020

Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience

1 reference

12 December 2020

10.1038/NRCLINONC.2010.63

Identifiers

DOI

1 reference

release_sdcvhickzvgltomxko5xap2zxa

22 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/sdcvhickzvgltomxko5xap2zxa

24 November 2022

mapped directly with Wikidata item

1 reference